Pipeline Overview

Based on the proprietary RNA-based Therapeutic Platform (RTP), RongCan Biotech aims to develop innovative nucleic acid-based medicines which demonstrate great promise in the prevention and treatment of human diseases by regulating target gene expression and protein function. RongCan owns independent intellectual property with respect to the world's leading nucleic acid delivery technical platform.

mRNA：
Single-stranded RNA, which is synthesized from a DNA template using the in vitro transcription (IVT) approach, carries with genetic information and guides protein synthesis.

Mechanism of Action：
The mRNA encoding for specific antigens is delivered into the immune cells and mediates the production of antigens, which activate the immune system and induce a specific immune response.